Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexFemale
• Healthy volunteersNo

You may be able to join if

• Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
• Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• There will be no limitations on number of prior lines of therapy
• Trial is open to non-English speaking patients
• Trial is open to patients referred from community practice

You cannot join if

• Patients who are < 18 years old
• Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
• Patients who are incarcerated
• Patients who are unable to provide consent / lack decision-making capacity

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Treatments listed in the registry

• Atovaquone (Drug): Given PO
• Biopsy (Procedure): Undergo biopsy
• Computed Tomography (Procedure): Undergo CT
• Paracentesis (Procedure): Undergo paracentesis

Na · Single Group · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• biopsy: Part of the study plan
• CT scans: Part of the study plan

Main goals

• Progression free survival (PFS) (From initiation of atovaquone to progression or death, assessed up to 1 year)

Other goals

• Clinical benefit rate
• Overall survival (OS)
• Incidence of adverse events

Planned enrollment: 28 (estimated).

• Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT05998135

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Sep 30, 2026. Public record; not medical advice.